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Abstract
Background: Sphingomyelin (SM) is the major phospholipid in cell membranes and in lipoproteins.
In human plasma, SM is mainly found in atherogenic lipoproteins; thus, high levels of SM may
promote atherogenesis.
Methods: We investigated in a median follow up of 6.0 years the association of SM with the
incidence of a combined endpoint (myocardial infarction and cardiovascular death) in stable and
unstable patients, and its relation to other marker of atherosclerosis in 1,102 patients with
angiographically documented CAD and 444 healthy controls.
Results and discussion: Logistic regression analysis showed that SM categorized by median was
associated with an elevated risk for CAD (HR 3.2, 95%CI 2.5–4.0, p < 0.05). SM levels were
correlated with apoB (r = 0.34) and triglyceride levels (r = 0.31). In patients with stable angina (n
= 614), SM categorized by median was not related to incidence of a combined endpoint
(cardiovascular death and myocardial infarction) (p = 0.844 by Log-rank test). However, in patients
with acute coronary syndrome (n = 488), elevated SM was related to the combined endpoint (p <
0.05 by Log-rank test), also in a multivariate Cox regression analysis including potential
confounders (HR 1.8, 95%CI 1.0–3.3, p < 0.05).
Conclusion: The results of our study reveal that 1) human plasma SM levels are a risk factor for
CAD; 2) the pro-atherogenic property of plasma SM might be related to metabolism of apoB-
containing or triglyceride-rich lipoproteins; and 3) plasma SM levels are a predictor for outcome of
patients with acute coronary syndrome.
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Introduction
Atherogenesis is initiated by the interaction of cholesterol-
rich lipoproteins with the arterial wall [1]. Many processes
have been implicated in early atherogenesis, including
lipoprotein oxidation [2], lipoprotein retention and
aggregation [1,3], endothelial alteration, macrophage
chemotaxis and foam cell formation, and smooth muscle
cell migration and alteration [4]. However, subendothe-
lial retention and aggregation of atherogenic lipoproteins
have emerged as the primary pathogenic processes [1].
Two sets of evidence indicate that aortic and plasma
sphingomyelin (SM) levels are closely related to the devel-
opment of atherosclerosis: First, it has long been known
that SM accumulates in atheromas formed in humans and
in animal models [5-7]. The low-density lipoprotein
(LDL) extracted from human atherosclerotic lesions is
much richer in SM than the LDL from plasma [8,9]. A sub-
stantial amount of the SM found in arteries and athero-
sclerotic lesions appears to arise from synthesis in arterial
tissue [10]. The SM concentration is also significantly
increased in macrophages treated with acetyl-LDL plus an
acyl-CoA:cholesterol acyltransferase inhibitor [11]. How-
ever, even in atherosclerotic lesions, the apparent rate of
SM formation is relatively low compared with the rate of
total phospholipid synthesis [12], suggesting that other
factors might also contribute to intimal SM accumulation.
Secondly, plasma SM levels are increased in human famil-
ial hyperlipidemias, especially in familial hypercholester-
olemia [13], and also in animal models of atherosclerosis
[14-16]. The concentration of SM is an important determi-
nant of the susceptibility of lipoprotein SM to sphingomy-
elinase (SMase) [9,16], which might in turn cause
atherogenic lipoprotein aggregation and atherosclerosis
[17]. These findings suggest that plasma SM levels may be
a risk factor for atherosclerosis.
In order to further investigate the role of SM in atheroscle-
rosis, we measured plasma SM levels in 1,102 patients
with angiographically proven coronary artery disease
(CAD) and 444 healthy controls and its relationship to
other risk factors and clinical outcome.
Methods
Study population
Between November 1996 and July 2000, we recruited
1,102 patients suffering from symptoms of CAD (614
patients with stable angina [SAP]; 488 with acute coronary
syndrome [ACS]) admitted to the second medical depart-
ment of the Johannes Gutenberg-University Mainz or the
Bundeswehrzentralkrankenhaus Koblenz for diagnostic
coronary angiography. The sole inclusion criterion was
the presence of a stenosis > 30% in at least one major cor-
onary artery. The study is described in detail elsewhere
Table 1: Demographic and clinical measures in cases and controls. For cases and controls categorical variables are presented as 
percentage of patients; chi-square test was used for group differences; and continuous variables are presented as mean values 
(standard deviation) or *median values (25/75th interquartiles) because of skewed distribution. The p values were obtained by *Mann-
Whitney test. #: data for 913 patients for ejection fraction, data for 200 controls/1026 patients for apoA-I and apoB, for 200 controls/
905 patients for Hs-CRP, and for 200 controls/1060 patients for Lp(a).
Variable Cases n = 1102 Controls n = 444 P- value
Age, years 61.1 (10.1) 59.7 (7.4) <0.001
BMI, kg/m2 27.2 (3.7) 26.7 (4.3) 0.02
Sex, male % 74.7 72.7 0.43
Current smoking, % 27.3 11.0 < 0.001
Diabetes mellitus, % 21.6 3.7 <0.001
Hypertension, % 71.9 28.6 <0.001
Family history of CAD, % 38.2 20.1 <0.001
Statins, % 35.8 6.3 < 0.001
ACE inhibitors, % 47.8 8.3 <0.001
Angiotensin receptor 
blockers, %
5.0 3.8 0.327
Ejection fraction <40%#, % 7.6 - -
Hs-CRP*, mg/l# 4.4 (1.9/12.4) 1.5 (0.9/3.8) <0.001
PLTP, U/l 25.5 (9.8) 22.4 (7.4) <0.001
CETP, U/l 49.9 (20.9) 41.4 (17.4) <0.001
Total cholesterol, mg/dl 219.7 (45.7) 238.4 (41.8) <0.001
LDL cholesterol, mg/dl 141.0 (40.1) 155.5 (35.1) <0.001
HDL cholesterol, mg/dl 48.8 (14.7) 59.4 (15.9) <0.001
Triglyceride*, mg/dl 141 (102/193) 120 (87/167) <0.001
Apolipoprotein A-I, g/l# 1.31 (0.24) 1.62 (0.28) <0.001
Apolipoprotein B, g/l# 1.20 (0.28) 1.19 (0.23) 0.3
Lipoprotein(a), mg/dl# 36.3 (38.9) 24.2 (30.4) <0.001Nutrition & Metabolism 2006, 3:5 http://www.nutritionandmetabolism.com/content/3/1/5
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[18]. Exclusion criteria were lack of CAD as defined above
and evidence of significant concomitant disease, in partic-
ular severe valvular heart disease, known cardiomyopa-
thy, malignancy, inflammatory diseases, or a febrile
condition. Patients completed a questionnaire about
smoking habits, history of diabetes mellitus, hyperten-
sion, hyperlipoproteinemia, current drug use, and family
history of premature CAD (documented in one first-
degree relative before age 65). Diabetes mellitus was diag-
nosed in patients who had previously undergone dietary
treatment or received additional oral antidiabetic or insu-
lin medication or who had a current fasting blood sugar
level > 125 mg/dl; hypertension was diagnosed in patients
who had received antihypertensive treatment or had been
diagnosed as hypertensive (blood pressure > 160/90
mmHg); hyperlipoproteinemia was diagnosed in patients
who had been given lipid-lowering medication or had a
history of cholesterol levels > 240 mg/dl.
Patients were followed up for a median 6.0 years. The
majority of the patients presented at our clinic for follow-
up; a small number of them were interviewed by tele-
phone by trained medical staff. At follow-up, information
was obtained about cardiovascular death or nonfatal
myocardial infarction (n = 163). Information about the
cause of death or clinical events was obtained from hospi-
tal or general practitioner charts.
Healthy control subjects (n = 444) were recruited either
from general practitioners' offices in the course of routine
check-up visits or by newspaper announcement, which
briefly described the study design and invited healthy
individuals aged ≥40 years to participate in this study as
control subjects. Of the individuals who presented, we
selected those without any clinical or anamnestic evi-
dence of atherosclerosis and without evidence of any
pathological ECG pattern. All individuals who presented
received reports of any classical and treatable risk factors
for personal use.
In general, study and control patients were of German
nationality and were inhabitants of the Rhein-Main Area.
The study was approved by the ethics committee of the
University of Mainz. Participation was voluntary, and
each study subject gave written informed consent.
Laboratory methods
Blood was drawn from all subjects under standardized
conditions after an overnight fasting period and before
coronary angiography was performed. Samples were
placed on ice immediately and within 30 minutes were
centrifuged at 4,000 rpm for 10 minutes, divided into
aliquots, and frozen at -80°C until analysis.
Plasma SM levels were measured as described previously
[19]. SM was analyzed concurrently in patients and con-
trols and the laboratory personnel was unaware of the
individual's study allocation.
Plasma lipid levels (total cholesterol, Roche Diagnostics,
Germany; high-density lipoprotein cholesterol (HDL-C),
Rolf Greiner Biochemica, Flacht, Germany; LDL-C, calcu-
lated according to the Friedewald formula; triglycerides,
Roche Diagnostics, Germany) were determined immedi-
ately. Apolipoprotein A-I (apoA-I) and apoB concentra-
tions were determined by immunoturbodimetric assays
(Tina-quant, Roche Diagnostics, Germany). The lipopro-
tein(a) [Lp(a)] concentration was determined using an
enzyme-linked immunosorbent assay-based method sup-
plied by Immuno Ltd. (Dunton Green, Kent, UK). C-reac-
tive protein (CRP) was determined by a highly sensitive,
latex particle-enhanced immunoassay (detection range of
0 to 20 mg/l); the between-day imprecision of this assay
(n = 21) was 2.14% and 1.44% at mean levels of 1.90 mg/
l and 4.33 mg/l (Roche Diagnostics, Germany).
Statistical analysis
Demographic and clinical variables of cases and controls
were compared by Chi square test for categorical and
ANOVA test for continuous variables. Because of skewed
distribution for triglyceride and Hs-CRP, median values
were presented and the Mann-Whitney test applied for
these variables. The distributions for plasma concentra-
Plasma SM concentrations in patients and controls (p < 0.001  by ANOVA) Figure 1
Plasma SM concentrations in patients and controls (p < 0.001 
by ANOVA). *: mean with 95% confidence intervals, #: mini-
mum/maximum.Nutrition & Metabolism 2006, 3:5 http://www.nutritionandmetabolism.com/content/3/1/5
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tions of SM were skewed and all analyses were calculated
with log-transformed values; however, exponential values
are presented. For correlation of SM with further variables,
Pearson's correlation coefficients were calculated, using
log-transformed values of SM, triglycerides and high-sen-
sitive CRP (Hs-CRP) for each group individually. Case
and control r-values were compared using Fisher's Z-trans-
formation. We aimed to assess any evidence of association
between SM and CAD in models, assuming both linear
and nonlinear effects. We thus divided cases and controls
into two groups stratified by median (48.1 mg/dl) on the
basis of the overall study population and applied a logistic
regression model.
Survival was analyzed by the Kaplan-Meyer method and
Log-rank test. In all survival analyses, the endpoint was a
combined endpoint of death of cardiovascular causes and
nonfatal myocardial infarction. Data on patients who
died of other causes were censored at the time of death.
The association of SM with outcome was evaluated by Cox
regression analyses adjusted for potential confounders. In
these analyses, SM was considered in two groups stratified
by median; other markers were considered either as con-
tinuous (log-transformed) or categorical variables. Haz-
ard ratios (HRs) and 95 % confidence intervals (CIs) are
reported with 2-tailed probability values. P < 0.05 was
considered to be significant. All analyses were carried out
using SPSS 11.5 software.
Results
Demographic and clinical measures
Baseline data regarding case and control subjects are out-
lined in Table 1. As expected, the prevalence of classical
risk factors such as current smoking (27.3% versus
11.0%), history of diabetes mellitus (21.6% versus 3.7%),
hypertension (71.9% versus 28.6%), and family history of
premature CAD (38.2% versus 20.1%) was more frequent
in cases than in controls. Furthermore, a significantly
higher rate of ACE inhibitor (47.8% versus 8.3%) and sta-
tin (35.8% versus 6.3 %) prescriptions was noted in cases
than in controls. The higher prescription of statins might
well have caused the significantly lower levels of total cho-
lesterol and LDL-C levels noted in the cases. HDL-C and
apoA-I levels were lower in cases than in controls, as
expected. Lp(a) and triglycerides but not apoB levels were
higher in the patients. Phospholipid transfer protein
(PLTP) and cholesterol ester transfer protein (CETP) activ-
ity and Hs-CRP concentrations were also elevated in
patients.
Relationship between SM and CAD
Figure 1 shows that patients with CAD had higher plasma
SM levels than healthy controls (mean 51.8 mg/dl versus
mean 44.9 mg/dl; p < 0.001 by ANOVA).
Logistic regression analysis showed that plasma SM cate-
gorized by median was associated with an elevated risk for
CAD (HR 3.2, 95%CI 2.5–4.0, for subjects with SM ≥48.1
mg/dl compared to subjects with SM < 48.1 mg/dl).
Correlation with other risk factors
To investigate the possibility that plasma SM levels could
act as a marker for triglyceride-rich lipoproteins or apoB-
containing lipoprotein metabolism, we performed corre-
lation analyses as outlined in Table 2. In all subjects cor-
relations were found between plasma SM and apoB (r =
0.34) and between plasma SM and triglycerides (r = 0.31).
Moreover, these relationships were significantly stronger
in patients than in controls (for apoB, r = 0.36 for patients
and r = 0.25 for controls, respectively, p = 0.03; for triglyc-
eride, r = 0.32 for patients and r = 0.11 for controls, respec-
tively, p < 0.001, see Table 2).
Table 2: Pearson coefficients of correlation between SM and other continuous variables (age, further lipid variables, CETP, PLTP, and 
Hs-CRP), stratified by CAD. Comparison of r-values of cases and controls by Fisher's Z-transformation (p- and Z-values presented)
Sphingomyelin‡
All Cases Controls p-value (Z-value)
Age, years - 0.03 0.06 -0.03 0.11 (1.6)
BMI, kg/m2 0.08 0.09 0.06 0.59 (-0.54)
Total cholesterol, mg/dl 0.17 0.25 0.14 0.04 (2.03)
LDL cholesterol, mg/dl 0.13 0.20 0.13 0.2 (1.28)
HDL cholesterol, mg/dl - 0.14 -0.08 -0.01 0.12 (-0.24)
Triglyceride, mg/dl‡ 0.31 0.32 0.11 <0.001 (3.92)
Apolipoprotein A-I, g/l -0.05 0.05 -0.07 0.03 (2.13)
Apolipoprotein B, g/l 0.34 0.36 0.25 0.03 (2.15)
Lipoprotein(a), mg/dl 0.03 0.01 -0.04 0.37 (0.89)
CETP, U/l -0.11 -0.03 -0.19 < 0.001 (2.88)
PLTP, U/l 0.01 -0.06 0.08 0.01 (-2.94)
Hs-CRP, mg/l‡ 0.05 0.05 0.12 0.21 (1.25)
‡: log-transformed variablesNutrition & Metabolism 2006, 3:5 http://www.nutritionandmetabolism.com/content/3/1/5
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Weak associations were found between plasma SM levels
and total cholesterol (r = 0.17), LDL-C (r = 0.13), HDL-C
(r = -0.14) and CETP (r = -0.11) in all subjects. The corre-
lations between SM and total cholesterol, LDL-C, and
HDL-C were stronger in patients; however, the correlation
between SM and CETP was stronger in controls.
There were no or only very weak associations between
plasma SM levels and other risk factors, including age,
BMI, apoA-I, PLTP, and Lp(a). It is of interest that SM con-
centrations were not related to Hs-CRP levels (r = 0.05).
For the possible relationship of plasma SM to categorical
risk factors, ANOVA tests were performed separately for
patients and controls. Statin intake seemed to influence
plasma concentrations in patients, but a significant trend
for lower plasma SM concentrations was not observed in
patients receiving statin treatment (p = 0.068). Sex, diabe-
tes (in patients), and left ventricular ejection fraction
(dichotomized for <40%) did not affect the concentration
of plasma SM (see Table 3). The small number of controls
with diabetes might explain the significantly elevated SM
plasma concentrations in this subgroup. We found a trend
for higher plasma SM concentrations in smokers. How-
ever, SM was significantly decreased in patients receiving
ACE inhibitors (51.3 mg/dl versus 49.7 mg/dl, p = 0.015)
but not in controls taking this medication (44.3 mg/dl
versus 42.8 mg/dl, p = 0.309) (Table 3).
Cardiovascular risk in patients
In patients with stable angina, SM was not related to the
combined endpoint (p = 0.844 by log-rank test, see Figure
1a). However, in a group of patients with acute coronary
syndrome and plasma SM concentrations above the
median (48.1 mg/dl), a higher proportion of patients
with myocardial infarction and cardiovascular death was
found (p < 0.05 by Log-rank test, see Figure 1b). For fur-
ther statistical evaluation of these data, univariate (model
1, Table 4) and multivariate (model 2, model 3, Table 4)
Cox regression analyses were performed. The multivariate
model including age, sex, body -mass index, smoking, dia-
betes mellitus, arterial hypertension, hyperlipoproteine-
mia, family history of CHD, statins, log-transformed
triglycerides, and apoB showed that patients with ACS and
SM ≥48.1 mg/dl were at an elevated risk for further cardi-
ovascular events (HR 1.8, 95%CI 1.0–3.3, p = 0.048, Table
4).
Discussion
In the present study we confirmed our previous observa-
tion that plasma SM levels are a risk factor for CAD [19].
Furthermore, we revealed that plasma SM levels showed
the strongest correlation with plasma apoB and triglycer-
ides levels, suggesting that human plasma SM levels could
be a marker for triglyceride-rich or apoB-containing lipo-
protein remnant accumulation found in human athero-
sclerosis as we suggested previously [20]. Moreover, we
Table 3: Mean of plasma SM levels according to cardiovascular risk factors.
Controls Patients
n SM in mg/dl p-value n SM in mg/dl p-value
Sex
female 121 44.7 ± 1.2 0.398 279 51.3 ± 1.25 0.210
male 323 43.9 ± 1.21 823 50.3 ± 1.24
Diabetes mell.
- 428 43.9 ± 1.21 <0.001 863 50.7 ± 1.24 0.362
+ 16 52.8 ± 1.26 239 49.9 ± 1.26
Hypertension
- 317 44.0 ± 2.29 0.628 309 51.5 ± 1.25 0.077
+ 127 44.4 ± 1.24 793 50.2 ± 1.25
Smoking
- 395 43.9 ± 1.21 0.048 801 50.2 ± 1.24 0.057
+ 49 46.4 ± 1.21 301 51.6 ± 1.26
Statins
- 411 44.0 ± 1.21 0.46 690 51.0 ± 1.24 0.068
+ 28 45.3 ± 1.19 395 49.7 ± 1.26
ACE inhibitors
- 407 44.3 ± 1.21 0.309 575 51.3 ± 1.26 0.015
+ 37 42.8 ± 1.26 527 49.7 ± 1.23
Ejection fraction
<40% - - - 69 50.4 ± 1.24 0.325
>40% - - 844 51.4 ± 1.21Nutrition & Metabolism 2006, 3:5 http://www.nutritionandmetabolism.com/content/3/1/5
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found that plasma SM levels are a predictor for event-free
survival of patients with acute coronary syndrome, sug-
gesting a possible link between plasma SM levels and the
instability of coronary plaques. We also found a not sig-
nificant trend for lower plasma SM concentrations in
patients under statin treatment. Diabetes mellitus or low
ejection fraction did not affect plasma SM concentrations.
Why is SM related to the atherosclerotic process? SM
might be a marker for an inflammatory effect, and inflam-
matory markers such as CRP have been shown to be
important risk factors for atherosclerosis [21]. However,
plasma SM levels did not correlate with Hs-CRP in our
study (Table 2). Thus, it is unlikely that SM acts as a surro-
gate inflammatory marker.
Plasma SM levels are related to atherogenic lipoprotein
aggregation, which is the initial step in the development
of atherosclerosis [17]. It is well known that SM content is
much higher in apoB-containing or triglyceride-rich lipo-
proteins than in HDL [22]. This may indicate that apoB-
containing or triglyceride-rich lipoproteins are athero-
genic but that HDL is not. It is also well known that aggre-
gated lipoproteins are prominent in atherosclerotic
lesions [3,23-26]. In addition, processes that promote
lipoprotein aggregation before or during retention dra-
Kaplan-Meyer survival plots for cardiovascular mortality according to SM plasma concentrations in patients with stable (Figure  2a) and unstable angina (Figure 2b) Figure 2
Kaplan-Meyer survival plots for cardiovascular mortality according to SM plasma concentrations in patients with stable (Figure 
2a) and unstable angina (Figure 2b).
Table 4: Cox regression analyses of SM stratified by median (48.1 mg/dl) in patients with acute coronary syndrome in univariate 
(model 1) and multivariate models (model 2 included age, sex, BMI, smoking, diabetes mellitus, arterial hypertension, and family 
history of CHD; model 3 further adjusted for statins, apoB, and log-transformed triglyceride)
SM <48.1 mg/dl SM ≥48.1 mg/dl P-value
OR Model 1 --- 0.6 0.049
95%CI 0.3–0.9
OR Model 2 --- 1.9 0.019
95%CI 1.1–3.4
OR Model 3 --- 1.8 0.048
95%CI 1.0–3.3Nutrition & Metabolism 2006, 3:5 http://www.nutritionandmetabolism.com/content/3/1/5
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matically increase the amount of lipoprotein retained
[27,28], which, in turn, might amplify the atherogenic
responses to this retention [1,28]. The mechanisms
responsible for increased retention as a result of aggrega-
tion include increased binding of the aggregates to the
subendothelial matrix [27,28] and decreased efflux of the
aggregates from the arterial wall due to their increased size
[30,31]. Atherogenic lipoprotein aggregation after hydrol-
ysis by sphingomyelinase is the most physiologically
plausible mechanism [32,9,33,34]. Hydrolysis of approx.
25% of the SM of LDL to ceramide in vitro by bacterial
SMase leads to the formation of aggregated and fused par-
ticles that are excellent inducers of macrophage foam cell
formation [28,32,34]. There is evidence to show that a
mammalian arterial-wall SMase may carry out a similar
reaction in atherosclerotic lesions in vivo [33]. Schissel et
al. [35,36] discovered a novel form of SMase called secre-
tory SMase, or S-SMase. Although S-Smase is secreted by
macrophages, it is secreted even more abundantly by
endothelial cells [37]. Thus, S-SMase could be present in
arteries before lesions develop and therefore might
explain very early lipoprotein aggregation [3]. Further evi-
dence implicating a role for S-SMase in lipoprotein aggre-
gation in atherosclerotic lesions includes its ability to
hydrolyze and aggregate atherogenic lipoprotein [9], its
increased secretion from endothelial cells treated with
cytokines that have been implicated in atherogenesis [39],
and its presence in atherosclerotic lesions as demosn-
trated by immunohistochemistry [38].
As we suggested previously [20], SM might be a surrogate
marker for the metabolism of triglyceride-rich and apoB-
containing lipoproteins. In the present study, we found
the strongest correlations between plasma SM and apoB
or triglycerides (Table 2). Humans spend most of their
lives in the postprandial state. The long-term effect of
repeated, prolonged, and exaggerated bouts of alimentary
lipemia may be disturbances in the metabolism of endog-
enous lipoproteins that are rich in SM and atherogenic
[39]. It is conceivable that postprandial SM remnants in
apoB-containing or triglyceride-rich lipoproteins may not
only serve as a clearance marker of these particles, but also
have their own impact on atherosclerosis. If somehow the
clearance of postprandial apoB-containing- or triglycer-
ide-rich lipoproteins was blocked, the SM-rich particles
could likely be aggregated in the arterial wall after encoun-
tering sphingomylinase there, and development or insta-
bility of atheroscerotic plaques could be the consequence.
However, epidemiological studies of postprandial SM lev-
els and atherosclerosis are still lacking.
Moreover, atherosclerotic LDLs exhibit an increase in SM
[9], which is believed to stimulate hydrolysis of LDL by
secreted Smase. In addition, the ceramide content of lipo-
proteins found in atherosclerotic lesions is increased (up
to a 50-fold enrichment as compared with plasma LDL)
[36]. These two mechanisms may be further involved in
apoptosis of affected cells such as smooth muscle cells or
macrophages via the SM/ceramide pathway, resulting in
destabilization of atherosclerotic plaques.
Conclusion
Overall, plasma SM is risk factor for CAD and a risk factor
for further cardiovascular events in patients with acute
coronary syndrome. Its relationship to apoB-containing
or triglycerides-rich lipoproteins as shown in our data
could partly explain its proatherogenic properties.
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